Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
Sawsan AlMukdadHazem ElewaDaoud Al-BadriyehPublished in: Journal of cardiovascular pharmacology and therapeutics (2020)
Based on current economic evaluations in the literature, implementing CYP2C19 genotype-guided therapy is a cost-effective approach in guiding the selection of medication in patients with ACS undergoing PCI.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- systematic review
- st segment elevation myocardial infarction
- acute myocardial infarction
- st elevation myocardial infarction
- coronary artery disease
- healthcare
- coronary artery bypass grafting
- emergency department
- life cycle
- stem cells
- heart failure
- mesenchymal stem cells
- atrial fibrillation